Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | Unmet needs and future avenues in the treatment of rhabdomyosarcoma

Julia Chisholm • 16 Aug 2021

Julia Chisholm, PhD, FRCPCH, The Royal Marsden NHS Foundation Trust, explains some of the ongoing work into improving treatment in rhabdomyosarcoma. She describes various potential avenues, including work investigating drugs that could potentiate the effects of radiotherapy, as well as work looking at the potential for immunotherapy and CAR-T cell approaches. Furthermore, she explains how molecular profiling could help in the development of more specific, targeted approaches against rhabdomyosarcoma in the future. Patients may require different approaches for optimal treatment, with the ultimate goal being an individualized and personalized approach. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.